Abstract

The therapeutic effectiveness of immune checkpoint inhibitors in cancer patients is quite profound. However, it is generally accepted that further progress is curtailed by accompanying adverse events and by low cure rates linked to the tumor microenvironment. The multitudes of immune processes altered by low-molecular-weight thiols published over the past decades suggest they have potential to alter tumor microenvironment processes which could result in an increase in immune checkpoint inhibitor survival rates. Based on one of the most studied and most potent low-molecular-weight thiols, β-mercaptoethanol (BME), it is proposed that clinical assessment be undertaken to identify any BME benefits with relevance for proliferation/differentiation of immune cells, lymphocyte exhaustion, immunogenicity of tumor antigens and inactivation of suppressor cells/factors. The BME alterations projected to be most effective are: maintenance/replacement of glutathione in lymphocytes via facilitation of cysteine uptake, inhibition of suppressor cells/soluble factors and inactivation of free-radical, reactive oxygen species.

Keywords:

References

1. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2), 205–214 (2015).
Medline CASGoogle Scholar
2. Martins F, Sofiya L, Sykiotis GP et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16(9), 563–580 (2019).
Medline CASGoogle Scholar
3. Lombardi A, Mondelli MU. Immune checkpoint inhibitors and the liver. From therapeutic efficacy to side effects. Aliment. Pharmacol. Ther. 50(8), 872–884 (2019).
MedlineGoogle Scholar
4. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381(16), 1535–1546 (2019).
Medline CASGoogle Scholar
5. Reddy SM, Reuben A, Wargo JA. Influences of BRAF inhibitors on the immune microenvironment and the rationale for combined molecular and immune targeted therapy. Curr. Oncol. Rep. 18(7), 42 (2016).
MedlineGoogle Scholar
6. Hu Z, Ding J, Ma Z et al. Quantitative evidence for early metastatic seeding in colorectal cancer. Nat. Genet. 51(7), 1113–1122 (2019).
Medline CASGoogle Scholar
7. Click RE. Anticancer activity and chemoprevention of xenobiotic organosulfurs in preclinical model systems. Oncol. Discov. 1, 4 (2013).
Google Scholar
8. Oliveira PVS, Laurindo FRM. Implications of plasma thiol redox in disease. Clin. Sci. (Lond.) 132(12), 1257–1280 (2018).
Medline CASGoogle Scholar
9. Iciek M, Wlodek L. Biosynthesis and biological properties of compounds containing highly reactive, reduced sulfane sulfur. Pol. J. Pharmacol. 53(3), 215–225 (2001).
Medline CASGoogle Scholar
10. Toohey JI. Sulfur signaling: is the agent sulfide or sulfane? Anal. Biochem. 413(2), 1–7 (2011).
Medline CASGoogle Scholar
11. Makinodan T, Albright JW, Good PI, Peter CP, Heidrick ML. Reduced humoral immune activity in long-lived old mice: an approach to elucidating its mechanisms. Immunology 31(6), 903–911 (1976).
Medline CASGoogle Scholar
12. Makinodan T, Albright JW. Restoration of impaired immune functions in aging animals. III. Effect of mercaptoethanol in enhancing the reduced primary antibody responsiveness in vivo. Mech. Ageing Dev. 11(1), 1–8 (1979).
Medline CASGoogle Scholar
13. Heidrick ML, Albright JW, Makinodan T. Restoration of impaired immune functions in aging animals. IV. Action of 2-mercaptoethanol in enhancing age-reduced immune responsiveness. Mech. Ageing Dev. 13(4), 367–378 (1980).
Medline CASGoogle Scholar
14. Heidrick ML, Hendricks LC, Cook DE. Effect of dietary 2-mercaptoethanol on the life span, immune system, tumor incidence and lipid peroxidation damage in spleen lymphocytes of aging BC3F1 mice. Mech. Ageing Dev. 27(3), 341–358 (1984).
Medline CASGoogle Scholar
15. Click RE. Obesity, longevity, quality of life: alteration by dietary 2-mercaptoethanol. Virulence 1(6), 509–515 (2010).
MedlineGoogle Scholar
16. Click RE. Longevity of SLE-prone mice increased by dietary 2-mercaptoethanol via a mechanism imprinted within the first 28 days of life. Virulence 1(6), 516–522 (2010).
MedlineGoogle Scholar
17. Click RE. Dietary supplemented 2-mercaptoethanol prevents spontaneous and delays virally induced murine mammary tumorigenesis. Cancer Biol. Ther. 14(6), 521–526 (2013).
Medline CASGoogle Scholar
18. Click RE. Alteration of radiation-sensitive processes associated with cancer and longevity by dietary 2-mercaptoethanol. J. Cancer Res. Ther. 10(1), 127–132 (2014).
MedlineGoogle Scholar
19. Pénzes L, Noble RC, Beregi E, Imre S, Izsák J, Regius O. Effect of 2-mercaptoethanol on some metabolic indices of ageing of CBA/Ca inbred mice. Mech. Ageing Dev. 45(1), 75–92 (1988).
Medline CASGoogle Scholar
20. Fehér E, Pénzes L. Effect of an antioxidant compound (2-mercaptoethanol) on the nerve terminals of the aging small intestine. Exp. Gerontol. 25(2), 135–140 (1990).
Medline CASGoogle Scholar
21. Fischer HD, Wustmann C, Rudolph E et al. Effect of 2-mercaptoethanol on posthypoxic and age related biochemical and behavioral changes in mice and rats. Biomed. Biochim. Acta 49(10), 1085–1090 (1990).
Medline CASGoogle Scholar
22. Beregi E, Regius O, Rajczy K, Boross M, Pénzes L. Effect of cigarette smoke and 2-mercaptoethanol administration on age-related alterations and immunological parameters. Gerontol. 37(6), 326–334 (1991).
Medline CASGoogle Scholar
23. Wong S, Kirkland JL, Schwanz HA et al. Effects of thiol antioxidant β-mercaptoethanol on diet-induced obese mice. Life Sci. 107(1-2), 32–41 (2014).
Medline CASGoogle Scholar
24. Click RE, Benck L, Alter BJ. Enhancement of antibody synthesis in vitro by mercaptoethanol. Cell. Immunol. 3(1), 155–160 (1972).
Google Scholar
25. Click RE, Benck L, Alter BJ. Immune responses in vitro. I. Culture conditions for antibody synthesis. Cell. Immunol. 3(2), 264–276 (1972).
Medline CASGoogle Scholar
26. Click RE, Benck L, Alter BJ, Lovchik JC. Immune responses in vitro. VI. Genetic control of the in vivo–in vitro discrepancies in 19S antibody synthesis. J. Exp. Med. 136(5), 1241–1257 (1972).
Medline CASGoogle Scholar
27. Peck AB, Click RE. Immune responses in vitro. VII. Differentiation of H-2 and non-H-2 alloantigens of the mouse by a dual mixed leukocyte culture. Transplant. 16(4), 331–338 (1973).
Medline CASGoogle Scholar
28. Heber-Katz E, Click RE. Immune responses in vitro. V. Role of mercaptoethanol in the mixed-leukocyte reaction. Cell. Immunol. 5(3), 410–418 (1972).
Medline CASGoogle Scholar
29. Heber-Katz E, Peck AB, Click RE. Immune responses in vitro. II. Mixed leukocyte interaction in a protein-free medium. Eur. J. Immunol. 3(7), 379–385 (1973).
MedlineGoogle Scholar
30. Peck AB, Katz-Heber E, Click RE. Immune responses in vitro. IV. A comparison of the protein-free and mouse serum supplemented mouse mixed lymphocyte interaction assays. Eur. J. Immunol. 3(8), 516–519 (1973).
Medline CASGoogle Scholar
31. Peck AB, Click RE. Immune responses in vitro. III. Enhancement of the mouse mixed lymphocyte interaction by isologous and homologous sera. Eur. J. Immunol. 3(7), 385–392 (1973).
Medline CASGoogle Scholar
32. Ohmori H, Yamauchi T, Yamamoto I. Augmentation of in vitro antibody response by disulfide compounds. I. Comparison between intermolecular and intramolecular disulfides. Jpn. J. Pharmacol. 37(1), 13–19 (1985).
Medline CASGoogle Scholar
33. Goodman MG, Weigle WO. Nonspecific activation of murine lymphocytes. I. Proliferation and polyclonal activation induced by 2-mercaptoethanol and α-thioglycerol. J. Exp. Med. 145(3), 473–489 (1977).
Medline CASGoogle Scholar
34. Ohmori H, Yamauchi T, Yamamoto I. Augmentation of the antibody response by lipoic acid in mice. I. Analysis of the mode of action in in vitro culture system. Jpn. J. Pharmacol. 42(1), 135–140 (1986).
MedlineGoogle Scholar
35. Chen C, Hirsch JG. The effects of mercaptoethanol and of peritoneal macrophages on the antibody-forming capacity of nonadherent mouse spleen cells in vitro. J. Exp. Med. 136(3), 604–617 (1972).
Medline CASGoogle Scholar
36. Opitz HG, Opitz U, Lemke H, Hewlett G, Schreml W, Flad HD. The role of fetal calf serum in the primary immune response in vitro. J. Exp. Med. 145(4), 1029–1038 (1977).
Medline CASGoogle Scholar
37. Ohmori H, Yamamoto I. Augmentation of in vitro antibody response by disulfide compounds. II. T cell-mediated augmentation by oxidized dithiothreitol, an intramolecular disulfide. Immunopharmacology 7(3–4), 159–165 (1984).
Medline CASGoogle Scholar
38. Sato H, Shiiya A, Kimata M et al. Redox imbalance in cystine/glutamate transporter-deficient mice. J. Biol. Chem. 280(45), 37423–37429 (2005).
Medline CASGoogle Scholar
39. Chused TM, Kassan SS, Mosier DE. Macrophage requirement for the in vitro response to TNP-Ficoll: a thymic independent antigen. J. Immunol. 116(6), 1579–1581 (1976).
Medline CASGoogle Scholar
40. Zhang M, Xia L, Yang Y et al. PD-1 blockade augments humoral immunity through ICOS-mediated CD4+ T cell instruction. Int. Immunopharmacol. 66(1), 127–138 (2019).
Medline CASGoogle Scholar
41. Ly IA, Mishell RI. Separation of mouse spleen cells by passage through columns of Sephadex G-10. J. Immunol. Methods 5(3), 239–247 (1974).
Medline CASGoogle Scholar
42. Opitz HG, Opitz U, Lemke H, Flad HD, Hewlett G, Schlumberger HD. Humoral primary immune response in vitro in a homologous mouse system: replacement of fetal calf serum by a 2-mercaptoethanol or macrophage-activated fraction of mouse serum. J. Immunol. 119(6), 2089–2094 (1977).
Medline CASGoogle Scholar
43. Nordin AA. The in vitro immune response to a T-independent antigen. I. The effect of macrophages and 2-mercaptoethanol. Eur. J. Immunol. 8(11), 776–781 (1978).
Medline CASGoogle Scholar
44. Igarashi T, Okada M, Kishimoto T, Yamamura Y. In vitro induction of polyclonal killer T cells with 2-mercaptoethanol and the essential role of macrophages in this process. J. Immunol. 118(5), 1697–1703 (1977).
Medline CASGoogle Scholar
45. Peck AB, Andersson LC, Wigzell H. Secondary in vitro responses of T lymphocytes to non-H-2 alloantigens. J. Exp. Med. 145(4), 802–818 (1977).
Medline CASGoogle Scholar
46. Macphail S, Yron I, Stutman O. Primary in vitro cytotoxic T cell response to non-major histocompatibility complex alloantigens in normal mice. J. Exp. Med. 156(2), 610–621 (1982).
Medline CASGoogle Scholar
47. Cerottini J-C, Enger HD, MacDonald HR, Brunner KT. Generation of cytotoxic T lymphocytes in vitro. I. Response of normal and immune mouse spleen cells in mixed leukocyte cultures. J. Exp. Med. 140(3), 703–717 (1974).
Medline CASGoogle Scholar
48. Engers HD, MacDonald HR, Cerottini JC, Brunner KT. Effect of delayed addition of 2-mercaptoethanol on the generation of mouse cytotoxic T lymphocytes in mixed leukocyte cultures. Eur. J. Immunol. 5(3), 223–225 (1975).
Medline CASGoogle Scholar
49. Walunas TL, Lenschow DJ, Bakker CY et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1(5), 405–413 (1994).
Medline CASGoogle Scholar
50. Yang YF, Zou JP, Mu J et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res. 57(18), 4036–4041 (1997).
Medline CASGoogle Scholar
51. Redelman D, Hudig D. The mechanism of cell-mediated cytotoxicity. I. Killing by murine cytotoxic T lymphocytes requires cell surface thiols and activated proteases. J. Immunol. 124(2), 870–878 (1980).
Medline CASGoogle Scholar
52. Macho-Fernandez E, Brigl M. The extended family of CD1d-restricted NKT cells: sifting through a mixed bag of TCRs, antigens, and functions. Front. Immunol. 6, 362 (2015).
MedlineGoogle Scholar
53. Smyth MJ, Thia KY, Street SE et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191(4), 661–668 (2000).
Medline CASGoogle Scholar
54. Swann JB, Uldrich AP, van Dommelen S et al. Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood 113(25), 6382–6385 (2009).
Medline CASGoogle Scholar
55. Bellone M, Ceccon M, Grioni M et al. iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells. PLoS ONE 5(1), e8646 (2010).
MedlineGoogle Scholar
56. Rhost S, Löfbom L, Rynmark B-M et al. Identification of novel glycol ligands activating a sulfatide-reactive, CD1d-restricted, Type II natural killer T lymphocyte. Eur. J. Immunol. 42(11), 2851–2860 (2012).
Medline CASGoogle Scholar
57. McEwen-Smith RM, Salio M, Cerundolo V. The regulatory role of invariant NKT cells in tumor immunity. Cancer Immunol. Res. 3(5), 425–435 (2015).
Medline CASGoogle Scholar
58. Dasgupta S, Kumar V. Type II NKT cells: a distinct CD1d-restricted immune regulatory NKT cell subset. Immunogenetics 68(8), 665–676 (2016).
Medline CASGoogle Scholar
59. Ristow SS, Starkey JR, Stanford DR, Davis WC, Brooks CG. Cell surface thiols, but not intracellular glutathione, are essential for cytolysis by a cloned murine natural killer cell line. Immunol. Invest. 14(5), 401–414 (1985).
Medline CASGoogle Scholar
60. van den Brink RM, Boggs SS, Herberman RB, Hiserodt JC. The generation of natural killer (NK) cells from NK precursor cells in rat long term bone marrow cultures. J. Exp. Med. 172(1), 303–313 (1990).
MedlineGoogle Scholar
61. Kuppen PJ, Eggermont AM, Marinelli A, de Heer E, van de Velde CJ, Fleuren GJ. Induction of lymphokine-activated killer activity in rat splenocyte cultures: the importance of 2-mercaptoethanol and indomethacin. Cancer Immunol. Immunother. 33(1), 28–32 (1991).
Medline CASGoogle Scholar
62. Stacey NH, Craig GK. Role of thiols in human peripheral blood natural killer and killer lymphocyte activities. Experientia 45(2), 180–181 (1989).
Medline CASGoogle Scholar
63. Yamauchi A, Bloom ET. Requirement of thiol compounds as reducing agents for IL-2-mediated induction of LAK activity and proliferation of human NK cells. J. Immunol. 151(10), 5535–5544 (1993).
Medline CASGoogle Scholar
64. Furuke K, Shiraishi M, Mostowski HS, Bloom ET. Fas ligand induction in human NK cells is regulated by redox through a calcineurin-nuclear factors of activated T cell-dependent pathway. J. Immunol. 162(4), 1988–1993 (1999).
Medline CASGoogle Scholar
65. Delneste Y, Jeannin P, Sebille E, Aubry JP, Bonnefoy JY. Thiols prevent Fas (CD95)-mediated T cell apoptosis by down-regulating membrane Fas expression. Eur. J. Immunol. 26(12), 2981–2988 (1996).
Medline CASGoogle Scholar
66. Zheng X, Qian Y, Fu B et al. Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance. Nat. Immunol. 20(12), 1656–1667 (2019).
Medline CASGoogle Scholar
67. Kahan SM, Zajac AJ. Immune exhaustion: past lessons and new insights from lymphocytic choriomeningitis virus. Viruses 11(2), 156 (2019).
CASGoogle Scholar
68. Yi JY, Cox MA, Zajac AJ. T-cell exhaustion: characteristics, causes and conversion. Immunology 129(4), 474–481 (2010).
Medline CASGoogle Scholar
69. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15(8), 486–499 (2015).
Medline CASGoogle Scholar
70. West EE, Jin HT, Rasheed AU et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J. Clin. Invest. 123(6), 2604–2615 (2013).
Medline CASGoogle Scholar
71. Cayota A, Vuillier F, Gonzalez G, Dighiero G. In vitro antioxidant treatment recovers proliferative responses of anergic CD4+ lymphocytes from human immunodeficiency virus-infected individuals. Blood 87(11), 4746–4753 (1996).
Medline CASGoogle Scholar
72. Iwata S, Hori T, Sato N et al. Adult T cell leukemia (ATL)-derived factor/human thioredoxin prevents apoptosis of lymphoid cells induced by L-cystine and glutathione depletion: possible involvement of thiol-mediated redox regulation in apoptosis caused by pro-oxidant state. J. Immunol. 158(7), 3108–3117 (1997).
Medline CASGoogle Scholar
73. Hadzic T, Li L, Cheng N, Walsh SA, Spitz DR, Knudson CM. The role of low molecular weight thiols in T lymphocyte proliferation and IL-2 secretion. J. Immunol. 175(12), 7965–7972 (2005).
Medline CASGoogle Scholar
74. Smith KA. Commentary: The interleukin-2 T cell system: a new cell growth model. Front. Immunol. 6, 414 (2015).
MedlineGoogle Scholar
75. Zmuda J, Friedenson B. Changes in intracellular glutathione levels in stimulated and unstimulated lymphocytes in the presence of 2-mercaptoethanol or cysteine. J. Immunol. 130(1), 362–364 (1983).
Medline CASGoogle Scholar
76. Dröge W, Eck HP, Gmünder H, Mihm S. Requirement for pro-oxidant and antioxidant states in T cell mediated immune responses-Relevance for the pathogenetic mechanisms of AIDS? Klin. Wochenschr. 69(21–23), 1118–1122 (1991).
Medline CASGoogle Scholar
77. Dröge W, Eck HP, Gmünder H, Mihm S. Modulation of lymphocyte functions and immune responses by cysteine and cysteine derivatives. Am. J. Med. 91(3C), S140–S144 (1991).
Google Scholar
78. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. N-Acetylcysteine – a safe antidote for cysteine/glutathione deficiency. Curr. Opin. Pharmacol. 7(4), 355–359 (2007).
Medline CASGoogle Scholar
79. Dröge W, Holm E. Role of cysteine and glutathione in HIV infection and other diseases associated with muscle wasting and immunological dysfunction. FASEB J. 11(13), 1077–1089 (1997).
Medline CASGoogle Scholar
80. Perry LL, Benacerraf B, Greene MI. Regulation of the immune response to tumor antigen. IV. Tumor antigen-specific suppressor factor(s) bear I-J determinants and induce suppressor T cells in vivo. J. Immunol. 121(6), 2144–2147 (1978).
Medline CASGoogle Scholar
81. Ting CC, Rodrigues D. Switching on the macrophage-mediated suppressor mechanism by tumor cells to evade host immune surveillance. Proc. Natl Acad. Sci. USA 77(7), 4265–4269 (1980).
Medline CASGoogle Scholar
82. McKeown MJ, Hall ND, Corvaian JR. Defective monocyte accessory function due to surface sulfhydryl oxidation in rheumatoid arthritis. Clin. Exp. Immunol. 56(3), 607–613 (1984).
Medline CASGoogle Scholar
83. Hong H, Gu Y, Zhang H et al. Depletion of CD4+ CD25+ regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model. Clin. Exp. Immunol. 159(1), 93–99 (2010).
Medline CASGoogle Scholar
84. Suarez N, Alfaro C, Dubrot J et al. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo. Int. J. Cancer 129(2), 374–386 (2011).
Medline CASGoogle Scholar
85. Simpson TR, Li F, Montalvo-Ortiz W et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210(9), 1695–1710 (2013).
Medline CASGoogle Scholar
86. Kapp JA, Pierce CW, Theze J, Benacerraf B. Modulation of immune responses by suppressor T cells. Fed. Proc. 37(10), 2361–2364 (1978).
Medline CASGoogle Scholar
87. Pierce CW, Kapp JA. Activities of nonspecific and specific suppressor T-cell factors in immune responses. Agents Actions Suppl. 7, 126–133 (1980).
Medline CASGoogle Scholar
88. Aune TM. Role and function of antigen nonspecific suppressor factors. Crit. Rev. Immunol. 7(2), 93–130 (1987).
Medline CASGoogle Scholar
89. Eardley DD, Gershon RK. Induction of specific suppressor T cells in vitro. J. Immunol. 117(1), 313–318 (1976).
Medline CASGoogle Scholar
90. Wu J, Levy EM, Black PH. 2-Mercaptoethanol and N-acetylcysteine enhance T cell colony formation in AIDS and ARC. Clin. Exp. Immunol. 77(1), 7–10 (1989).
Medline CASGoogle Scholar
91. Efimova O, Szankasi P, Kelley TW. Ncf1 (p47phox) is essential for direct regulatory T cell mediated suppression of CD4+ effector T cells. PLoS ONE 6(1), e16013 (2011).
Medline CASGoogle Scholar
92. Irimajiri N, Bloom ET, Makinodan T. Suppression of murine natural killer cell activity by adherent cells from aging mice. Mech. Ageing Dev. 31(2), 155–162 (1985).
Medline CASGoogle Scholar
93. Parekh VV, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J. Clin. Invest. 115(9), 2572–2583 (2005).
Medline CASGoogle Scholar
94. Koren HS, Hodes RJ. Effect of tumor cells on the generation of cytotoxic T lymphocytes in vitro. I. Accessory cell functions of mouse tumor cells in the generation of cytotoxic T lymphocytes in vitro: replacement of adherent phagocytic cells by tumor cells or 2-mercaptoethanol. Eur. J. Immunol. 7(6), 394–400 (1977).
Medline CASGoogle Scholar
95. Gelderman KA, Hultqvist M, Pizzolla A et al. Macrophages suppress T cell responses and arthritis development in mice by producing reactive oxygen species. J. Clin. Invest. 117(10), 3020–3028 (2007).
Medline CASGoogle Scholar
96. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 70(1), 68–77 (2010).
Medline CASGoogle Scholar
97. Yan Z, Garg SK, Kipnis J, Banerjee R. Extracellular redox modulation by regulatory T cells. Nat. Chem. Biol. 5(10), 721–723 (2009).
Medline CASGoogle Scholar
98. Schnaper HW, Aune TM. Suppression of immune responses to sheep erythrocytes by the lymphokine soluble immune response suppressor (SIRS) in vivo. J. Immunol. 137(3), 863–867 (1986).
Medline CASGoogle Scholar
99. Laurence J, Gottlieb AB, Kunkel HG. Soluble suppressor factors in patients with acquired immune deficiency syndrome and its prodrome. Elaboration in vitro by T lymphocyte-adherent cell interactions. J. Clin. Invest. 72(6), 2072–2081 (1983).
Medline CASGoogle Scholar
100. Brown-Galatola CH, Hall ND. Impaired suppressor cell activity due to surface sulphydryl oxidation in rheumatoid arthritis. Br. J. Rheumatol. 31(9), 599–603 (1992).
Medline CASGoogle Scholar
101. Macphail S, Stutman O. Suppressor T cells in a primary in vitro response to non-major histocompatibility alloantigens. J. Exp. Med. 156(5), 1398–1414 (1982).
Medline CASGoogle Scholar
102. Corse E, Gottschalk RA, Allison JP. Strength of TCR-peptide/MHC interactions and in vivo T cell responses. J. Immunol. 186(9), 5039–5045 (2011).
Medline CASGoogle Scholar
103. Park B, Lee S, Kim E et al. Redox regulation facilitates optimal peptide selection by MHC class I during antigen processing. Cell 27(2), 369–382 (2006).
Google Scholar
104. Chowell D, Morris LGT, Grigg CM et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359(6375), 582–587 (2018).
Medline CASGoogle Scholar
105. Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. Nat. Rev. Cancer 12(4), 307–313 (2012).
Medline CASGoogle Scholar
106. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 348(6230), 69–74 (2015).
Medline CASGoogle Scholar
107. Zaretsky JM, Garcia-Diaz A, Shin DS et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375(9), 819–829 (2016).
Medline CASGoogle Scholar
108. Melvold RW, Kohn HI, Dunn GR. History and genealogy of the H-2Kb mutants from the C57BL/6Kh colony. Immunogenetics 15(2), 177–185 (1982).
Medline CASGoogle Scholar
109. Festenstein H. Immunogenetic and biological aspects of in vitro lymphocyte allotransformation (MLR) in the mouse. Transplant. Rev. 15, 62–88 (1973).
Medline CASGoogle Scholar
110. Snell GD. Methods for the study of histocompatibility genes. J. Genet. 49, 87–108 (1948).
Medline CASGoogle Scholar
111. Melief CJM, DeWaal LP, Van der Meulen MY, Melvold RW, Kohn HI. Fine specificity of alloimmune cytotoxic T lymphocytes directed against H-2K. A Study with K^b Mutants. J. Exp. Med. 151(5), 993–1013 (1980).
Medline CASGoogle Scholar
112. Melief CJM, Schwartz RS, Kohn HI, Melvold RW. Dermal histocompatibility and in vitro lymphocyte reactions of three new H-2 mutants. Immunogenetics 2, 337–348 (1975).
Google Scholar
113. Adelmann A, Sherburne C, Condie RM, Click RE. Genetic control of permanently accepted allografts. Transplant. Proc. 19(1 Pt 1), 890–893 (1987).
Medline CASGoogle Scholar
114. Yamaga KM, Pfaffenbach GM, Pease LR et al. Biochemical studies of H-2K antigens from a group of related mutants. I. Identification of a shared mutation in B6-H-2bm5 and B6-H-2bm16. Immunogenetics 17(1), 19–29 (1983).
Medline CASGoogle Scholar
115. Melief CJM, van der Meulen MY, Postma P. CML typing of serologically identical H-2 mutants. Distinction of 19 specificities on the cells of four mouse strains carrying z1 locus mutations and the strain of origin. lmmunogenetics 5, 43–56 (.1977).
Google Scholar
116. Wettstein PJ, Bailey DW, Mobraaten LE, Klein JA, Frelinger JA. T-lymphocyte response to H-2 mutants. I. Proliferation is dependent on Ly 1⁺2⁺ cells. J. Exp. Med. 147(5), 1395–1404 (1978).
Medline CASGoogle Scholar
117. Click RE, Adelmann AM, Azar MM. Immune responses in vitro. XIII. MLR detectability of Mls^a, Mls^c, Mls^b, and Mls^d encoded products. J. Immunol. 134(5), 2948–2952 (1985).
Medline CASGoogle Scholar
118. Molnar-Kimber KL, Sprent J. Evidence that strong Mls determinants are nonpolymorphic. Transplantation 31(5), 376–378 (1981).
Medline CASGoogle Scholar
119. Click RE, Azar MM, Anderson VE. Immune responses in vitro. XII. Two independently segregating loci control Mls product(s). J. Immunol. 128(4), 1502–1506 (1982).
Medline CASGoogle Scholar
120. Click RE, Adelmann AM. Genetic complexity of Mls. J. Immunogenet. 15(1–3), 39–47 (1988).
Medline CASGoogle Scholar
121. Abe R, Ryan JJ, Finkelman FD, Hodes RJ. T cell recognition of Mls: T cell clones demonstrate polymorphism between Mls^a, Mls^c, and Mls^d. J. Immunol. 138(2), 373–379 (1987).
Medline CASGoogle Scholar
122. Abe R, Ryan JJ, Hodes RJ. Clonal analysis of the Mls system. A reappraisal of polymorphism and allelism among Mls^a, Mls^c, and Mls^d. J. Exp. Med. 165(4), 1113–1129 (1987).
Medline CASGoogle Scholar
123. Ryan JJ, Mond JJ, Finkelman FD. The Mls^d-defined primary mixed lymphocyte reaction: a composite response to Mls^a and Mls^c determinants. J. Immunol. 138(12), 4085–4092 (1987).
Medline CASGoogle Scholar
124. Janeway CA, Lerner EA, Jason JM, Jones B. T lymphocytes responding to Mls-locus antigens are Lyt-1⁺2- and I-A restricted. Immunogenetics 10(5), 481–497 (1980).
MedlineGoogle Scholar
125. Hämmerling U, Toulon M, Chun M, Palfree S, Hoffmann MK. Bidirectionality of mixed lymphocyte stimulation (Mls) response. Effects of Mls^b stimulator cells on Mls^a helper cells. J. Immunol. 140(8), 2543–2548 (1988).
Medline CASGoogle Scholar
126. Frankel WN, Kudy C, Coffin JM, Huber BT. Linkage of Mls genes to endogenous mouse mammary tumour viruses of inbred mice. Nature 349(6309), 526–528 (1991).
Medline CASGoogle Scholar
127. Pullen AM, Choi Y, Kushnir E, Kappler J, Marrack P. The open reading frames in the 3′ long terminal repeats of several mouse mammary tumor virus integrants encode V/∼3-specific superantigens. J. Exp. Med. 175(1), 41–47 (1992).
Medline CASGoogle Scholar
128. Snell GD, Stimpfling JH. Genetics of tissue transplantation. Biology of the Laboratory Mouse. (2nd Edition). Green EL (Ed.). McGraw-Hill, NY, USA, 457 (1966).
Google Scholar
129. Hauptfeld V, Klein J. A new histogenetic method for minor histocompatibility antigen typing. J. Immunol. 118(2), 423–426 (1977).
Medline CASGoogle Scholar
130. Wu S, Thomas DW. Syngeneic responses by murine thymocytes: a role for non-MHC and non-Mls genes. J. Immunol. 134(1), 10–15 (1985).
Medline CASGoogle Scholar
131. Nakashima I, Nagase F, Isobe K et al. Induction and characterization of minor histocompatibility antigens. Specific primary cytotoxic T lymphocyte responses in vitro. J. Immunol. 140(3), 723–729 (1988).
MedlineGoogle Scholar
132. Roopenian DC, Click RE. A new cytotoxic lymphocyte defined antigen coded by a gene closely linked to the H-3 locus. Immunogenetics 10(4), 333–341 (1980).
Medline CASGoogle Scholar
133. Click RE. Complexity of minor histocompatibility loci. Hum. Immunol. 14(3), 220–233 (1985).
Medline CASGoogle Scholar
134. Goodman MG, Weigle WO. Nonspecific activation of murine lymphocytes. II. Parameters of the interaction between splenic lymphocytes and radiolabeled 2-mercaptoethanol in vitro. J. Immunol. 120(5), 1453–1459 (1978).
Medline CASGoogle Scholar
135. Goodman MG, Fidler JM, Weigle WO. Nonspecific activation of murine lymphocytes. III. Nonspecific activation of murine lymphocytes. III. Cells responding mitogenically to 2-mercaptoethanol are typical unstimulated lymphocytes. J. Immunol. 121(5), 899–1904 (1978).
Google Scholar
136. Goodman MG, Fidler JM, Weigle WO. Nonspecific activation of murine lymphocytes. IV. Proliferation of a distinct, late maturing lymphocyte subpopulation induced by 2-mercaptoethanol. J. Immunol. 121(5), 1905–1913 (1978).
Medline CASGoogle Scholar
137. Goodman MG, Weigle WO. Nonspecific activation of murine lymphocytes. V. Role of cellular collaboration between T and B lymphocytes in the proliferative and polyclonal responses to 2-mercaptoethanol. J. Immunol. 122(4), 1433–1439 (1979).
Medline CASGoogle Scholar
138. Goodman MG, Weigle WO. Nonspecific activation of murine lymphocytes. VI. Mediation of synergistic interaction between T and B lymphocytes by a cell-associated, reciprocally acting lymphocyte proliferation helper. J. Exp. Med. 149(3), 644–657 (1979).
Medline CASGoogle Scholar
139. Goodman MG, Weigle WO. Nonspecific activation of murine lymphocytes. VII. Functional correlates of molecular structure of thiol compounds. J. Immunol. 126(1), 20–26 (1981).
Medline CASGoogle Scholar
140. Igarashi T, Okada M, Kishimoto T, Yamamura Y. In vitro induction of polyclonal killer T cells with 2-mercaptoethanol and the essential role of macrophages in this process. J. Immunol. 118(5), 1697–1703 (1977).
Medline CASGoogle Scholar
141. Place DE, Kanneganti T-D. Cell death-mediated cytokine release and its therapeutic implications. J. Exp. Med. 216(7), 1474–1486 (2019).
Medline CASGoogle Scholar
142. Heidrick ML, Makinodan T. Presence of impairment of humoral immunity in nonadherent spleen cells of old mice. J. Immunol. 111(5), 1502–1506 (1973).
Medline CASGoogle Scholar
143. Segre D, Segre M. Humoral immunity in aged mice. II. Increased suppressor T cell activity in immunologically deficient old mice. J. Immunol. 116(3), 735–738 (1976).
Medline CASGoogle Scholar
144. Chang MP, Tanaka JL, Stosic-Grujicic S et al. Restoration of impaired immune functions in aging animals. VI. Differential potentiating effect of 2-mercaptoethanol on young and old murine spleen cells. Int. J. Immunopharmacol. 4(5), 429–436 (1982).
Medline CASGoogle Scholar
145. Makinodan T, Albright JW. Restoration of impaired immune functions in aging animals. II. Effect of mercaptoethanol in enhancing the reduced primary antibody responsiveness in vitro. Mech. Ageing Dev. 10(5), 325–340 (1979).
Medline CASGoogle Scholar
146. Fong TC, Makinodan T. Preferential enhancement by 2-mercaptoethanol of IL-2 responsiveness of T blast cells from old over young mice is associated with potentiated protein kinase C translocation. Immunol. Lett. 20(2), 149–154 (1989).
Medline CASGoogle Scholar
147. Nauss KM, Connor AM, Newberne PM. Alterations in immune function in rats caused by dietary lipotrope deficiency: effect of culture medium, 2-mercaptoethanol and mitogen dose on the in vitro lymphocyte transformation response. J. Nutr. 112(12), 2342–2352 (1982).
Medline CASGoogle Scholar
148. Franklin RA, Li YM, Arkins S, Kelley KW. Glutathione augments in vitro proliferative responses of lymphocytes to concanavalin A to a greater degree in old than in young rats. J. Nutr. 120(12), 1710–1717 (1990).
Medline CASGoogle Scholar
149. Dussault I, Miller SC. Decline in natural killer cell-mediated immunosurveillance in aging mice – a consequence of reduced cell production and tumor binding capacity. Mech. Ageing Dev. 75(2), 115–129 (1994).
Medline CASGoogle Scholar
150. Mikael N, Mirza NM, Zaharian BI et al. Genetic control of the decline of natural killer cell activity in aging mice. Growth Dev. Aging 58(1), 3–12 (1994).
Medline CASGoogle Scholar
151. Sabry M, Lowdell MW. Tumor-primed NK cells: waiting for the green light. Front. Immunol. 4, e408 (2013).
MedlineGoogle Scholar
152. Ferrández MD, Correa R, Del Rio M, De La Fuente M. Effects in vitro of several antioxidants on the natural killer function of aging mice. Exp. Gerontol. 34(5), 675–685 (1999).
Medline CASGoogle Scholar
153. De La Fuente M, Miquel J, Catalán MP, Víctor VN, Guayerbas N. The amount of thiolic antioxidant ingestion needed to improve several immune functions is higher in aged than in adult mice. Free Radic. Res. 36(2), 119–126 (2002).
MedlineGoogle Scholar
154. Ali AA, Bilodeau JF, Sirard MA. Antioxidant requirements for bovine oocytes varies during in vitro maturation, fertilization and development. Theriogenology 59(3–4), 939–949 (2003).
Medline CASGoogle Scholar
155. Yang YJ, Wu PF, Long LH et al. Reversal of aging-associated hippocampal synaptic plasticity deficits by reductants via regulation of thiol redox and NMDA receptor function. Aging Cell 9(5), 709–721 (2010).
Medline CASGoogle Scholar
156. Marquardt H, Sapozink MD, Zedeck MS. Inhibition by cysteamine-HCl of oncogenesis induced by 7,12-dimethylbenz(alpha)anthracene without affecting toxicity. Cancer Res. 34(12), 3387–3390 (1974).
Medline CASGoogle Scholar
157. Tatsuta M, Iishi H, Yamamura H, Baba M, Mikuni T, Taniguchi H. Inhibitory effect of prolonged administration of cysteamine on experimental carcinogenesis in rat stomach induced by N-methyl-N'-nitro-N-nitrosoguanidine. Int. J. Cancer 41(3), 423–426 (1988).
Medline CASGoogle Scholar
158. Tatsuta M, Iishi H, Baba M, Taniguchi H. Tissue norepinephrine depletion as a mechanism for cysteamine inhibition of colon carcinogenesis induced by azoxymethane in Wistar rats. Int. J. Cancer 44(6), 1008–1011 (1989).
Medline CASGoogle Scholar
159. Tatsuta M, Iishi H, Baba M. Inhibition by cysteamine of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague–Dawley rats. Int. J. Cancer 44(3), 529–533 (1989).
Medline CASGoogle Scholar
160. Tatsuta M, Iishi H, Baba M, Taniguchi H. Attenuating effect of the monoamine oxidase inhibitor furazolidone on the anti-carcinogenetic effect of cysteamine on gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Int. J. Cancer 48(4), 605–608 (1991).
Medline CASGoogle Scholar
161. Harman D. Prolongation of the normal life span by radiation protection chemicals. J. Gerontol. 12(3), 257–263 (1957).
Medline CASGoogle Scholar
162. Harman D. Aging: overview. Ann. NY Acad. Sci. 928, 1–21 (2001).
Medline CASGoogle Scholar
163. Bluestone JA, Lopez C. Suppression of the immune response in tumor-bearing mice. I. Response to virus-producing tumor cells and non-virus-producing tumor cells. J. Natl Cancer Inst. 63(5), 1215–1220 (1979).
Medline CASGoogle Scholar
164. Hoffeld JT. Agents which block membrane lipid peroxidation enhance mouse spleen cell immune activities in vitro: relationship to the enhancing activity of 2-mercaptoethanol. Eur. J. Immunol. 11(5), 371–376 (1981).
Medline CASGoogle Scholar
165. Rathbun WB, Holleschau AM, Cohen JF, Nagasawa HT. Prevention of acetaminophen- and naphthalene-induced cataract and glutathione loss by CySSME. Invest. Ophthalmol. Vis. Sci. 37(5), 923–929 (1996).
Medline CASGoogle Scholar
166. Nagasawa HT, Shoeman DW, Cohen JF, Rathbun WB. Protection against acetaminophen-induced hepatotoxicity by L-CySSME and its N-acetyl and ethyl ester derivatives. J. Biochem. Toxicol. 11(6), 289–295 (1996).
Medline CASGoogle Scholar
167. Choe C, Shin YW, Kim EJ et al. Synergistic effects of glutathione and β-mercaptoethanol treatment during in vitro maturation of porcine oocytes on early embryonic development in a culture system supplemented with L-cysteine. J. Reprod. Dev. 56(6), 575–582 (2010).
Medline CASGoogle Scholar
168. Click RE. A review: alteration of in vitro reproduction processes by thiols – emphasis on 2-mercaptoethanol. J. Reprod. Dev. 60(6), 399–405 (2014).
Medline CASGoogle Scholar
169. Moshtagh PR, Emami SH, Sharifi AM. Differentiation of human adipose-derived mesenchymal stem cell into insulin-producing cells: an in vitro study. J. Physiol. Biochem. 69(3), 451–458 (2013).
Medline CASGoogle Scholar
170. Harman D. Origin and evolution of the free radical theory of aging: a brief personal history, 1954–2009. Biogerontology 10(6), 773–781 (2009).
Medline CASGoogle Scholar
171. Toohey JI. Sulphane sulphur in biological systems: a possible regulatory role. Biochem. J. 264(3), 625–632 (1989).
Medline CASGoogle Scholar
172. Déas O, Dumont C, Mollereau B et al. Thiol-mediated inhibition of FAS and CD2 apoptotic signaling in activated human peripheral T cells. Int. Immunol. 9(1), 117–125 (1997).
Medline CASGoogle Scholar
173. Zeng H, Trujillo ON, Moyer MP, Botnen JH. Prolonged sulforaphane treatment activates survival signaling in nontumorigenic NCM460 colon cells but apoptotic signaling in tumorigenic HCT116 colon cells. Nutr. Cancer 63(2), 248–255 (2011).
Medline CASGoogle Scholar
174. Chandra-Kuntal K, Singh SV. Diallyl trisulfide inhibits activation of signal transducer and activator of transcription 3 in prostate cancer cells in culture and in vivo. Cancer Prev. Res. 3(11), 1473–1483 (2010).
Medline CASGoogle Scholar
175. Wallace JL, Ferraz JG, Muscara MN. Hydrogen sulfide: an endogenous mediator of resolution of inflammation and injury. Antioxid. Redox Signal. 17(1), 58–67 (2012).
Medline CASGoogle Scholar
176. Miller TW, Wang EA, Gould S et al. Hydrogen sulfide is an endogenous potentiator of T cell activation. J. Biol. Chem. 287(6), 4211–4221 (2012).
Medline CASGoogle Scholar
177. Coletta C, Papapetropoulos A, Erdelyi K et al. Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. Proc. Natl Acad. Sci. USA 109(23), 9161–9166 (2012).
Medline CASGoogle Scholar
178. Edwards BS, Curry MS, Southon EA, Chong AS, Graf LH Jr. Evidence for a dithiol-activated signaling pathway in natural killer cell avidity regulation of leukocyte function antigen-1: structural requirements and relationship to phorbol ester- and CD16-triggered pathways. Blood 86(6), 2288–2301 (1995).
Medline CASGoogle Scholar
179. Hogg PJ. Targeting allosteric disulphide bonds in cancer. Nat. Rev. Cancer 13(7), 425–431 (2013).
Medline CASGoogle Scholar
180. Hansen JM, Jones DP. Thiols in cancer. In: Nutritional Oncology. Elsevier, Inc., MA, USA, 307–320 (2006).
Google Scholar
181. Sbodio JI, Snyder SH, Paul BD. Redox mechanisms in neurodegeneration: from disease outcomes to therapeutic opportunities. Antioxid. Redox Signal. 30(11), 1450–1499 (2019).
MedlineGoogle Scholar
182. Pruett SB, Obiri N, Kiel JL. Involvement and relative importance of at least two distinct mechanisms in the effects of 2-mercaptoethanol on murine lymphocytes in culture. J. Cell. Physiol. 141(1), 40–45 (1989).
Medline CASGoogle Scholar
183. Levring TB, Hansen AK, Nielsen BL et al. Activated human CD4+ T cells express transporters for both cysteine and cystine. Sci. Rep. 2, 266 (2012).
MedlineGoogle Scholar
184. Gmünder H, Eck HP, Benninghoff B, Roth S, Dröge W. Macrophages regulate intracellular glutathione levels of lymphocytes. Evidence for an immunoregulatory role of cysteine. Cell. Immunol. 129(1), 32–46 (1990).
Medline CASGoogle Scholar
185. Ghosh T, Barik S, Bhuniya A et al. Tumor-associated mesenchymal stem cells inhibit naive T cell expansion by blocking cysteine export from dendritic cells. Int. J. Cancer 139(9), 2068–2081 (2016).
Medline CASGoogle Scholar
186. Edinger AL, Thompson CB. Antigen presenting cells control T cell proliferation by regulating amino acid availability. Proc. Natl Acad. Sci. USA 99(3), 1107–1109 (2002).
Medline CASGoogle Scholar
187. Ishii T, Sugita Y, Bannai S. Regulation of glutathione levels in mouse spleen lymphocytes by transport of cysteine. J. Cell. Physiol. 133(2), 330–336 (1987).
Medline CASGoogle Scholar
188. Angelini G, Gardella S, Ardy M et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc. Natl Acad. Sci. USA 99(3), 1491–1496 (2002).
Medline CASGoogle Scholar
189. Ohmori H, Yamamoto I. Mechanism of augmentation of the antibody response in vitro by 2-mercaptoethanol in murine lymphocytes. I. 2-Mercaptoethanol-induced stimulation of the uptake of cystine, an essential amino acid. J. Exp. Med. 155(5), 1277–1290 (1982).
Medline CASGoogle Scholar
190. Ohmori H, Yamamoto I. Mechanism of augmentation of the antibody response in vitro by 2-mercaptoethanol in murine lymphocytes. II. A major role of the mixed disulfide between 2-mercaptoethanol and cysteine. Cell. Immunol. 79(1), 173–185 (1983).
Medline CASGoogle Scholar
191. Abdulle AE, Bourgonje AR, Kieneker LM et al. Serum free thiols predict cardiovascular events and all-cause mortality in the general population: a prospective cohort study. BMC Med. 18(1), 130 (2020).
Medline CASGoogle Scholar
192. Berk M, Dean O, Cotton SM et al. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J. Affect. Disord. 135(1–3), 389–394 (2011).
Medline CASGoogle Scholar
193. Demedts M, Behr J, Buhl R et al. IFIGENIA study group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 353(21), 2229–2242 (2005).
Medline CASGoogle Scholar
194. Wiel C, Le Gal K, Ibrahim MX et al. BACH1 stabilization by antioxidants stimulates lung cancer metastasis. Cell 178(2), 330–345 (2019).
Medline CASGoogle Scholar
195. Banne AF, Amiri A, Pero RW. Reduced level of serum thiols in patients with a diagnosis of active disease. J. Anti-Aging Med. 6(4), 327–334 (2003).
Medline CASGoogle Scholar
196. Koning AM, Meijers WC, Pasch A. Serum free thiols in chronic heart failure. Pharmacol. Res. 111, 452–458 (2016).
Medline CASGoogle Scholar
197. Damba T, Bourgonje AR, Abdulle AE et al. Oxidative stress is associated with suspected non-alcoholic fatty liver disease and all-cause mortality in the general population. Liver Int. 40(9), 2148–2159 (2020).
Medline CASGoogle Scholar
198. Click RE. Potentialalteration of COVID-19 by beta-mercaptoethanol. Future Microbiol. 15, 1313–1318 (2020).
CASGoogle Scholar

Vol. 17, No. 3

Metrics

Downloaded 161 times

History

Received 7 August 2020

Accepted 9 November 2020

Published online 24 December 2020

Published in print January 2021

Information

Keywords

Author contributions

R Click was the only contributor to this article.

Financial & competing interests disclosure

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

Potential alteration of tumor microenvironments by β-mercaptoethanol

Abstract

References